JIMD Reports

About JIMD Reports

JIMD Reports — Profile and Guide

JIMD Reports is the open-access companion publication to the Journal of Inherited Metabolic Disease (JIMD). It is the official open-access journal of the Society for the Study of Inborn Errors of Metabolism (SSIEM), devoted to case reports and short research reports on inherited metabolic disorders. Where the main JIMD journal carries major original articles, guidelines and reviews, JIMD Reports exists for sound, peer-reviewed findings and clinical observations that deserve a permanent place in the literature even when their interest is narrower, more specialised, or centred on a single patient, family or small cohort. That distinction is the key to understanding the title: it is not a lesser copy of its sister journal, and it is not a general medical case-report journal. It is a focused metabolic-medicine venue, sharing an editorial team and a submission system with JIMD, in which unusual presentations, previously unrecorded features, diagnostic lessons and small but rigorous studies can be recorded so that the next clinician facing a similar puzzle can find them.

This profile explains what JIMD Reports is, how it developed, what it publishes, who oversees it, how it is indexed, and how authors should judge whether a manuscript belongs here rather than in JIMD itself or in a broader genetics or paediatrics journal. The bibliographic record on this site lists the serial ISSNs 2192-8304 and 2192-8312 and the historic publisher Springer Berlin. Readers should also understand the publication's second phase: after its early life as a Springer book series, JIMD Reports became an online-only journal published on the Wiley platform for SSIEM, served by the same editorial team as JIMD. Both phases are described below, because citations from the Springer volumes and articles from the current journal belong to the same continuing serial identity.

Quick Facts

Frequency and article-processing details for the current journal phase are set by the publisher and the society and can change. A specific article-processing charge, waiver rule or issue schedule that is not stated on the current official journal or SSIEM pages is not publicly disclosed in a form this profile can responsibly reproduce, and authors should confirm the current terms inside the submission system before they submit. SSIEM has described a specific support route under which the society may cover the article-processing charge for eligible personal members who have no other funding source, subject to membership duration, payment status and confirmation after acceptance; that is a society policy to verify at submission, not a general promise that publication is free.

Identity: A Companion, Not a Duplicate

The inherited metabolic disorders are a large family of mostly rare, mostly genetic conditions in which an enzyme, transporter, cofactor pathway or related metabolic step does not work as it should. Individually many of these disorders are uncommon; together they form a substantial field that sits across paediatrics, adult medicine, neurology, genetics, laboratory biochemistry, dietetics, pharmacy and newborn screening. Progress in such a field depends unusually heavily on careful single-case and small-series reporting. A phenotype that has been seen only twice, a biochemical pattern that misled a laboratory, a treatment response in one family — observations of that size can change how the next patient is investigated.

JIMD Reports was created for exactly that kind of material. The publisher's description of the early volumes states the purpose plainly in substance: case and short research reports in inherited metabolic disorders, where a case report either highlights an unusual or previously unrecorded feature relevant to the disorder or serves as an important reminder of clinical or biochemical features of a Mendelian disorder. The current SSIEM description makes the sister-journal boundary explicit. JIMD and JIMD Reports are served by a single editorial team and a single manuscript submission and review process. JIMD Reports publishes scientifically sound research findings or clinical observations that warrant communication in the peer-reviewed literature but are of more limited interest to readers. That sentence does a great deal of work. It tells authors that referral from JIMD to JIMD Reports is a normal editorial outcome, that direct submission is also welcome, and that the standard is scientific soundness rather than breadth of impact alone.

Authors sometimes misread a companion title as an easier route that will accept weak work. The editorial model described by SSIEM points the other way. Because the same team handles both titles, a manuscript can be judged once for quality and then placed where its scope fits best. A well-documented case with a clear lesson can be right for JIMD Reports even if it would never anchor a full JIMD original article. A poorly documented case, a routine presentation with no new lesson, or a small study with methods that cannot support its conclusions fits neither title.

History and Development

JIMD Reports began with Springer as a book series linked to JIMD. Bibliographic records for the early volumes, published by Springer Berlin, Heidelberg, list the series ISSN as 2192-8304 and the electronic series ISSN as 2192-8312, with SSIEM as the responsible society and copyright holder alongside Springer. The 2012 volumes were presented as collections of case and research reports, with supplementary material offered through the publisher. The format suited the material at the time: edited volumes gathering peer-reviewed reports that might otherwise have been scattered or left unpublished, issued under the JIMD name that metabolic specialists already trusted.

The series continued through numbered volumes in the following years. Volumes in the mid-to-late 2010s, for example volumes 32, 35 and 42, carry a named editorial group familiar to JIMD readers — including Eva Morava, Matthias Baumgartner, Marc Patterson, Shamima Rahman, Johannes Zschocke and Verena Peters — and cover topics the Springer pages summarise as human genetics, metabolic diseases, paediatrics and molecular medicine. Those volume records matter for researchers tracing older citations: a JIMD Reports citation from this period may resolve to a Springer book chapter with its own book ISBN and chapter DOI, rather than to a journal article page of the kind the current title produces. Libraries and indexers therefore treat the early output as a book series, and readers should not be confused when a 2013 or 2017 reference looks different in form from a recent one.

The second phase recast the title as a journal in its own right. In the current arrangement described by SSIEM and Wiley, JIMD Reports is online only and open access, while JIMD itself remains the traditional print and online journal. The two are presented together on the society's journal pages, with separate instructions-for-authors documents reached from a common submission system, and with editors listed jointly. A secondary bibliographic listing for the journal phase records coverage from 2019 onward and a publication rhythm of six times a year; this profile treats that as a listing detail to check against the live journal site rather than as a permanent guarantee, because online journals commonly move toward continuous publication even when a nominal issue pattern remains in catalogues.

The move to Wiley for the JIMD family also explains why older secondary sources disagree about the publisher. Sources compiled during the Springer period list Springer Berlin or Springer Netherlands, depending on which JIMD-family title and year they describe. Sources compiled for the current period list Wiley. Neither is invented; they describe different phases. For the Journals World record, the important correction to hold in mind is that the Springer Berlin attribution is historic for JIMD Reports, while day-to-day submission, peer review and open-access publication are now handled through the Wiley-based JIMD operation overseen by SSIEM's editors. Anyone citing publisher information for a grant, tenure file or library record should state the phase and year they mean.

Two more recent developments show how the title is used inside the society. Since the start of 2022, SSIEM has invited JIMD Reports authors to record brief audio descriptions of their papers — called Shortcasts — alongside the longer JIMD podcast that began in 2020. The idea, as the society describes it, is to capture the short exchange a poster presenter has at a conference. That small detail reflects the journal's character: many of its papers begin as the kind of focused observation a specialist would stop to discuss at a meeting, and the journal gives that exchange a citable, searchable home.

Scope in Detail

The scope is inherited metabolic disease in humans and, where relevant to the sister journal's remit, in higher animals, approached from clinical, biochemical, genetic, experimental, methodological, theoretical, epidemiological, ethical and counselling angles. In practice, JIMD Reports papers cluster in several recognisable groups.

Single cases and small case series with a new feature. The core article type. A patient or family presents with a feature not previously recorded for the disorder, an unusual age or mode of presentation, an unexpected complication, or a finding that widens the known phenotype. The value lies in precise documentation: confirmed diagnosis, relevant laboratory and imaging evidence, timeline, and a discussion that separates what is new from what is already known.

Diagnostic reminders and pitfalls. Some reports earn their place not by novelty but by warning. A biochemical pattern that mimics another condition, a genetic variant that is easy to misinterpret, a screening result that behaves unexpectedly — a clear reminder can prevent the next misdiagnosis. Authors should be honest that the contribution is a reminder, explain why the pitfall still catches clinicians, and avoid dressing routine material up as a first observation.

Short research reports. Small cohort studies, laboratory method observations, natural-history fragments, treatment-response series and other compact studies that are complete and sound but limited in scale. The report should state its limits plainly. A short report is not a full original article cut down; it is a study whose question, methods and conclusions are all genuinely compact.

Treatment and management observations. Responses to dietary management, enzyme or cofactor therapy, transplantation, supportive care or newer targeted treatments, especially in disorders too rare for large trials. Single-patient treatment claims require particular care: concurrent changes, natural fluctuation and placebo-like effects in reporting must be discussed, and conclusions should stay proportionate to one case.

Genetics and variant interpretation. Reports centred on a variant, a genotype–phenotype correlation, or a family study that clarifies inheritance or counselling. Good papers in this group connect the molecular finding to biochemical or clinical evidence rather than presenting a variant list alone, and they follow current variant-classification practice.

Laboratory and biochemical medicine. Observations on assays, reference patterns, sample handling, newborn-screening follow-up and other measurement questions that change how a metabolic disorder is detected or monitored. Because JIMD readers include laboratory specialists, methodological detail matters as much as clinical narrative.

Long-term course and adult outcomes. As treatment improves, children with metabolic disorders grow into adults, and reports on transition, pregnancy, ageing, and late complications have become increasingly important. JIMD Reports is a natural home for carefully followed individual outcomes that build that picture one patient at a time.

Publisher, Society and Editorial Structure

SSIEM, the Society for the Study of Inborn Errors of Metabolism, is the owning society voice behind both JIMD titles. The society's stated aim for JIMD is to improve the management and understanding of inherited metabolic disorders by improving communication among workers in the field worldwide, and JIMD Reports shares that aim. SSIEM's journal page lists the senior editorial leadership jointly for the family: Matthias Baumgartner of University Children's Hospital Zürich as Senior Editor-in-Chief, Shamima Rahman of UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital as Editor-in-Chief, editors including Sean Froese, Johannes Zschocke and Nicola Brunetti-Pierri, and Verena Peters as Managing Editor, with communicating editors and an advisory board detailed on the journal website. Editorial rosters change, so authors should treat that list as the society's published snapshot and check the live journal masthead before addressing correspondence to a named person.

The practical structure for authors is simpler than the masthead. There is one submission and review process for the JIMD family, with separate instructions documents for JIMD and for JIMD Reports. An author can target JIMD Reports directly, submit to JIMD and be referred, or be offered transfer after review. In each case the manuscript is handled inside the same editorial operation, which helps explain why referral does not usually mean starting peer review from zero — although authors should never assume a transfer guarantees acceptance, and should revise in light of reviewer comments before resubmission under the companion title.

Peer review is described by the publisher and society as rigorous for the early volumes and remains the basis of the current journal's claim to be a peer-reviewed literature venue. Case reports raise specific ethical requirements that go beyond ordinary review: patient consent for publication, protection of identifying details, and care with images and family information. Those requirements are set out in the current instructions for authors; a manuscript that lacks the required consent statements may be returned regardless of its scientific interest. Specific consent wording, anonymisation rules and image policies that are not reproduced here could not be verified in a stable public form for this profile and must be taken from the live instructions at submission.

Indexing, Metrics and How to Read Them

JIMD Reports articles are designed to be found. The current journal is open access, so accepted articles are made freely available to read, download and share on publication — a major reason clinicians value the title, because the reader who needs a rare-case report is often outside a subscribing institution. Bibliographic listings for the journal record it in medical and scientific databases appropriate to its field, and articles carry DOIs under the current publisher's JIMD Reports prefix pattern, visible in recent papers. Authors should verify the precise current indexing list on the journal's own Wiley page before relying on any single database for a promotion or funding requirement, because database coverage lists are updated separately from journal websites and secondary listings can lag a title's move between publishers.

The metrics carried in this site's record — H-index 40, SJR 0.530 and a Q2 position — describe a mid-sized specialist title with a steady citation record. A Q2 placing in a narrow category means the journal sits in the second quarter of its peer group; it should be compared with other metabolic-medicine, medical-genetics and paediatric subspecialty titles, not with general medical journals whose citation pools are far larger. The H-index of 40 means forty publications in the indexed set have each been cited at least forty times, a respectable accumulation for a venue whose typical paper concerns a rare disorder and may be cited slowly, by a small worldwide community, over many years. A 2024 Journal Impact Factor figure of 1.8 appears in a secondary platform listing for the title; treat journal-level impact figures as year-specific, check the current Journal Citation Reports value if your institution requires one, and do not use any single year's figure to judge an individual case report, whose value is often clinical rather than citational.

For rare-disease work, discoverability often matters more than a metric. A JIMD Reports paper that is open access, indexed in biomedical search systems, and linked to the JIMD name will be found by the metabolic specialist, geneticist or laboratory physician searching that disorder years later. That long tail of clinical use is the title's real audience promise, and it is why careful titles, abstracts and keywords — naming the disorder, the gene or pathway where relevant, and the new feature — matter so much in this journal.

Submitting: Official Guidance Summarised

Submit through the JIMD family's online manuscript submission and review system, following the separate JIMD Reports instructions for authors linked from the SSIEM journal page. Before submitting, decide honestly which sister title fits. If the work is a guideline, a substantial original study, a major review or a finding of broad interest to the whole metabolic field, JIMD is the natural target. If it is a scientifically sound finding or observation of more limited interest — the society's own framing — JIMD Reports is the target, and saying so in a cover letter, with a sentence on the specific lesson or new feature, helps editors place it quickly.

Write the case or short report so a specialist reader can verify it without guesswork. Include the diagnostic evidence that establishes the disorder, the timeline, the relevant negative findings, the treatment and outcome where applicable, and a literature-aware discussion that states what was already known. Follow the instructions on article length, abstract structure, reference style, figures and supplementary material exactly; those technical requirements change and are not reproduced here, because reproducing a length limit or fee figure that later changes would mislead authors. Where a patient could be identified, complete the consent and ethics statements the system requires. Where funding, conflicts of interest or data availability must be declared, declare them in the form the publisher requests.

On cost, plan around open access. JIMD Reports is an open-access journal, so an article-processing charge normally applies unless a publisher agreement with the author's institution covers it or a society route applies. SSIEM describes a fund under which it may cover the charge for corresponding authors who are personal, non-corporate members, have held membership for at least three months before submission and have paid the current year's fee, have no other funding source, and are not covered by an institutional agreement — with the society confirming eligibility after acceptance. The exact charge amount is not stated in the sources used for this profile and is therefore not published here; check the journal's current open-access information before submission rather than relying on any third-party fee listing.

After acceptance, take the audio option seriously. The Shortcast invitation gives authors a short spoken summary attached to the JIMD podcast feed. For a case report, two minutes explaining what was unusual and what a clinician should remember can reach exactly the audience the paper was written for.

Who Should — and Should Not — Submit Here

Good fits include metabolic physicians, clinical geneticists, biochemical geneticists, laboratory scientists, specialist dietitians, neurologists, paediatricians and adult physicians who hold a well-documented observation in inherited metabolic medicine. Trainees are often well placed to write these papers, because case documentation is detailed work, but senior confirmation of diagnosis and consent is essential. Researchers with a compact, complete study that is too small for a full original article but too sound to leave in a conference abstract also fit well.

Poor fits include general case reports with no metabolic disorder at the centre, routine presentations with no new feature or lesson, variant announcements with no clinical or biochemical correlation, and treatment claims that outrun the evidence of a single case. Authors whose institution requires a specific quartile or impact-factor threshold should check the current values before choosing the title, and authors who need subscription-journal publication without any processing charge should confirm the funding route first rather than discovering the open-access model at acceptance.

Frequently Asked Questions

Is JIMD Reports the same as JIMD? No. They are sister publications sharing an editorial team and submission process. JIMD is the traditional print and online journal; JIMD Reports is the online-only open-access companion for case and short research reports and for sound findings of more limited interest.

What are its ISSNs? The serial record lists 2192-8304 and 2192-8312, originally the series and electronic series ISSNs from the Springer period and carried forward in journal listings for the title.

Who publishes it now? The historic volumes were published by Springer Berlin, Heidelberg. The current journal operates on the Wiley platform for SSIEM, as the society's official open-access journal. The difference reflects a change of phase, not two competing journals.

Is it peer reviewed? Yes. Contributions are described as rigorously peer reviewed, and the current title is handled through the JIMD family's editorial review process.

Is it open access? Yes, in its current journal form. Accepted articles are made freely available on publication. Charge, agreement and SSIEM member-fund details should be confirmed on the current journal pages at submission.

Can a paper move from JIMD to JIMD Reports? Yes — referral within the shared system is an intended route. A transfer offer is an editorial placement decision, not a rejection of the work's soundness, and not a guarantee of acceptance.

Sources and Verification Note

This profile was prepared from SSIEM's official journal pages, Springer's bibliographic records for the JIMD Reports volumes, the Wiley JIMD journal presence, and bibliographic listings for the current journal phase. Facts that could not be verified from those sources — including a current article-processing charge amount and a fixed issue schedule — are identified in the text as matters to confirm at submission rather than stated as settled facts.